Ozempic side effects in week one: what's real, what's overstated

What's this video probably claiming?

Based on the caption, @aliamediclinic is walking followers through what to expect in the first three to seven days after starting semaglutide (Ozempic). The three symptoms flagged, namely nausea and vomiting, dizziness, and constipation or stomach pain, are positioned as the standard early experience. This is a reasonable and clinically grounded topic for a clinic account to cover. The framing appears educational rather than promotional, which is a meaningful distinction. That said, presenting a shortlist of three symptoms without dose context, without discussion of severity gradation, and without any mention of when symptoms are serious enough to stop treatment is where this kind of content can quietly mislead a very large audience. At 152K views, the gap between what was said and what viewers walk away believing matters.

What does the science actually show?

The SUSTAIN and STEP trial programs give us the clearest picture here. In STEP 1 (Wilding et al., 2021, New England Journal of Medicine), nausea occurred in 44% of participants on semaglutide 2.4mg weekly versus 16% on placebo. Vomiting hit around 24%, diarrhea around 30%. Constipation was reported in roughly 24% of the semaglutide group. Dizziness is documented but less prominent, appearing more consistently as a downstream effect of reduced caloric intake and early dehydration than as a direct pharmacological action. Critically, the STEP data reflects the full titration schedule, typically starting at 0.25mg weekly for four weeks before escalating. The first-week side effect burden at the starting dose is generally milder than the caption framing suggests. Symptoms tend to peak during dose escalation phases, not just the initial injection.

Where does the social media noise diverge from clinical reality?

The caption lists constipation and stomach pain as a combined entry, but clinically these are quite different presentations with different management strategies. Constipation is actually more common with semaglutide than with liraglutide, possibly because of slower gastric emptying compounding colonic transit time. A 2022 systematic review by Jensterle et al. in Frontiers in Endocrinology noted that GI side effects are dose-dependent and titration-speed-dependent, meaning the clinical experience is highly variable. The video also omits a symptom that appears in the literature with some frequency: fatigue, which patients consistently report in early weeks but which rarely makes it into these symptom lists. More importantly, the caption does not appear to mention gastroparesis risk, which, while rare, has generated enough real-world signal that the FDA updated Ozempic labeling in 2023 to include it as a listed adverse event. Reducing a complex GI profile to three bullet points can create false reassurance.

What should you actually know?

If you are starting semaglutide, the first week at 0.25mg is typically the most manageable part of the process. The harder stretch for most people is the 0.5mg to 1mg escalation window. Staying well hydrated, eating smaller meals, and avoiding high-fat or high-sugar foods around injection time are the interventions with the most practical evidence behind them. A 2021 paper by Nauck et al. in Diabetes Care confirmed that slower titration meaningfully reduces discontinuation due to GI side effects. If vomiting is persistent beyond 48 hours, or if you are unable to keep fluids down, that is not a routine side effect to push through. It is a clinical reason to contact your prescriber. The three symptoms in this caption are real and common, but the absence of red flags, severity criteria, and dose-timing context means this video is only telling part of the story.